Nanocarry is developing a new class of therapeutics based on bioengineered nanoparticles with novel capabilities to treat oncology indications and brain diseases. Using a proprietary “Plug and Play” approach, Nanocarry’s AxS platform can be easily modified to deliver a wide array of biologics, safely and effectively, to the brain and beyond. Nanocarry’s first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.
Location: Israel
Employees: 1-10
Founded date: 2021